NASDAQ · Biotechnology

SKYE (SKYE) Stock

$0.58 -5.64% NASDAQ: SKYE Healthcare

Valuation

MetricValue
Price$0.58
Market Cap$20.39M
P/E Ratio-0.91
P/B Ratio1.44
P/S Ratio0.00
EPS (TTM)$-1.41
52-Week High$5.75
52-Week Low$0.57
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1.27%
ROA-71.93%
ROCE-290.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio3.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-8.0M$-18.0M$-35.0M$-30.0M$-58.0M
Net Profit$-9.0M$-19.0M$-38.0M$-27.0M$-56.0M
EPS$-5.00$-8.77$-5.37$-0.73$-1.41
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$10.0M$9.0M$12.0M$73.0M$28.0M
Total Liabilities$4.0M$12.0M$14.0M$5.0M$8.0M
Cash$9.0M$1.0M$1.0M$68.0M$6.0M
Borrowings$2.0M$2.0M$5.0M$0$0

Latest News

The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea Yahoo Finance · Jul 17, 2026 Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 GlobeNewswire · May 20, 2026 UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update GlobeNewswire · May 12, 2026 Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update GlobeNewswire · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-6.0M$-13.0M$-14.0M$-25.0M$-43.0M
Investing Cash Flow$0$5.0M$7.0M$-2.0M$-20.0M
Financing Cash Flow$7.0M$0$0$0$0
Net Cash Flow$7.0M$-8.0M$9.0M$58.0M$-63.0M
Free Cash Flow$-7.0M$-13.0M$-14.0M$-27.0M$-43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-126.20%
Quick Ratio3.30
Interest Coverage—
Return 1Y-83.79%
Return 3Y-88.46%
Return 5Y-98.53%

Ownership

Insiders Held1.17%
Institutions Held46.00%
Institutions Float Held46.55%
Institutional HolderSharesReport Date
5AM Venture Management, LLC9,681,7632026-03-31
Versant Venture Management, LLC2,007,7042026-03-31
Baker Bros. Advisors, LP1,575,2432026-03-31
Vanguard Capital Management LLC764,4572026-03-31
Sphera Funds Management Ltd.678,9282026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVM $1.18 +0.00% -0.23 $8.11M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%

About SKYE

SKYE is led by CEO Punit S. Dhillon, employs 16 people, headquartered in US, publicly traded since 2014.

SKYE stock trades at $0.58 with a market capitalization of $20.39M. The stock is valued at a price-to-earnings (P/E) ratio of -0.91, price-to-book of 1.44, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.57 and $5.75, and currently trades 89.9% below its 52-week high.

On profitability, SKYE generates a return on equity (ROE) of -1.27%, return on capital employed of -290.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides